#	Pagina
attuale pagina	/open-h2020/projects/224723/index.html

Opendata, web and dolomites

II-LCA SIGNED

Integrated Imaging in live Cell Analysis (II-LCA), for enhanced development and manufacturing of biologic and cell therapies.

Total Cost €

EC-Contrib. €

Partnership

Views

II-LCA project word cloud

Explore the words cloud of the II-LCA project. It provides you a very rough idea of what is the project "II-LCA" about.

successful incorporation drugs lca breakthrough dramatically accelerated manufacturing strengthen collaborations generate paradigms evolution therapeutics cell disease ia live cellular biological imaging indications treatment space team sciences therapies innovation valitacell automation instrumentation diverse recruitment life technologies expertise associate patients valitacells integral innovative benefit

Project "II-LCA" data sheet

The following table provides information about the project.

Coordinator	VALITACELL LTD Organization address address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK city: DUBLIN 2 postcode: V94 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Total cost	123˙746 €
EC max contribution	123˙746 € (100%)
Programme	1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
Code Call	H2020-INNOSUP-2019-02
Funding Scheme	CSA
Starting year	2019
Duration (year-month-day)	from 2019-09-15 to 2020-09-14

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VALITACELL LTD VALITACELL LTD Organization address address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK city: DUBLIN 2 postcode: V94 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN 2)	coordinator	123˙746.00

Map

Project objective

The successful recruitment and incorporation of an Innovation associate (IA), with expertise in live cell imaging, life sciences instrumentation and automation, into the Valitacell team is integral to the evolution of our technologies. The IA will dramatically enhance Valitacells capabilities in this space, strengthen existing collaborations, and generate further opportunities for future innovation. If successful, II-LCA will lead to the accelerated development of novel biological drugs and cellular therapeutics, for the treatment of diverse disease indications. European patients will benefit from increased access to targeted and innovative breakthrough therapies, through reduced cost of development and improved manufacturing paradigms.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "II-LCA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "II-LCA" are provided by the European Opendata Portal: CORDIS opendata.